CD47 expression is decreased in hematopoietic progenitor cells in patients with myelofibrosis

AUTOR(ES)

Nonino, A., Nascimento, J.M., Mascarenhas, C.C., Mazzeu, J.F., Pereira, R.W., Jacomo, R.H.

FONTE

Braz J Med Biol Res

DATA DE PUBLICAÇÃO

10/12/2018

RESUMO

Myelofibrosis (MF) is characterized by increased circulating hematopoietic progenitor cells (HPCs), abnormal cytokine levels, and the survival advantage of neoplastic progenitors over their normal counterparts, which leads to progressive disappearance of polyclonal hematopoiesis. CD47 is a surface glycoprotein with many functions, such as acting as a phagocytosis inhibitor of the expressing cell, that is increased in normal hematopoietic stem and progenitor cells mobilized into the blood and several human cancer-initiating cells, such as in acute myeloid leukemia. We compared CD47 expression in hematopoietic stem and progenitor cells of patients with MF and controls and found it to be decreased in progenitors of MF. Exposure of control HPCs to the cytokines transforming growth factor β and stromal-derived factor 1, which are important regulators of hematopoietic stem cell cycling and are overexpressed in patients with MF, did not modulate CD47 expression.

Documentos Relacionados

• The Thrombospondin Receptor CD47 (IAP) Modulates and Associates with α2β1 Integrin in Vascular Smooth Muscle Cells
• Mobilizing hematopoietic progenitor cells in donors with sickle cell trait is safe
• Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia
• Decreased Expression of the CD3ζ Chain in T Cells Infiltrating the Synovial Membrane of Patients with Osteoarthritis
• Minor histocompatibility antigen H-Y is expressed on human hematopoietic progenitor cells.